IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis. In-class switch has been hardly investigated for interleukin-17A inhibitors. We report the experience (2017-2018) of a tertiary medical center with interleukin-17A-inhibitor s...
Spremljeno u:
Glavni autori: | , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Medical Journals Sweden,
2019-05-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Primjerak 1 | Dostupno |